医学
鲁索利替尼
内科学
血栓形成
真性红细胞增多症
骨髓纤维化
血小板增多症
白细胞增多症
入射(几何)
贫血
疾病
血液学
骨髓增生性肿瘤
队列
外科
胃肠病学
临床试验
低风险
红细胞压积
队列研究
肿瘤科
比例危险模型
单变量分析
血管疾病
疾病严重程度
生存分析
作者
Francesca Palandri,Elena Rossi,Massimo Breccia,Elena Maria Elli,Chiara Sartor,Alessandra Dedola,Alessandra Dedola,Erika Morsia,Novella Pugliese,Roberto Latagliata,Francesco Mendicino,Alessia Tieghi,Giulia Benevolo,Gianni Binotto,Mirko Farina,Alessandra D’Addio,Mario Tiribelli,Daniela Cilloni,Monica Crugnola,Flavia Salvatore
出处
期刊:Leukemia
[Springer Nature]
日期:2026-11-17
标识
DOI:10.1038/s41375-026-03183-y
摘要
European LeukemiaNet defines the clinical signs and symptoms (CSSs) of polycythemia vera (PV) as progressive splenomegaly, leukocytosis, thrombocytosis, inadequate hematocrit control, and cardiovascular risk factors. In PV patients receiving hydroxyurea, CSSs indicate a phenotype with higher thrombosis risk across the standard risk categories. However, the prognostic value of CSSs for thrombosis or progression to secondary myelofibrosis (SMF) or acute leukemia (AL) during second-line ruxolitinib therapy remains unknown. We assessed the incidence rate ratios (IRRs) of thrombosis and disease progression during ruxolitinib treatment, and the prognostic impact of CSSs at treatment initiation, in 254 PV patients from the PV-ARC multicenter cohort. CSSs were identified in 50.4% of patients, with similar proportions in low- and high-risk groups (50% vs 50.5%). The IRRs for thrombosis and progression to SMF/AL were 1.0 and 4.2 %p‑y, respectively. Conventional thrombotic risk categories did not predict thrombosis or progression. In contrast, CSSs were associated with higher IRRs of both thrombosis (1.8 vs 0 %p‑y, p = 0.05) and progression (6.0 vs 2.3 %p‑y, p = 0.02). Persistent or progressive leukocytosis was the strongest predictor of disease progression. In conclusion, CSSs refine conventional risk stratification by improving prediction of thrombosis and disease progression during ruxolitinib, supporting their integration into routine clinical assessment.
科研通智能强力驱动
Strongly Powered by AbleSci AI